Advertisement
Singapore markets closed
  • Straits Times Index

    3,300.04
    -3.15 (-0.10%)
     
  • S&P 500

    5,196.37
    +15.63 (+0.30%)
     
  • Dow

    38,963.52
    +111.25 (+0.29%)
     
  • Nasdaq

    16,386.17
    +36.92 (+0.23%)
     
  • Bitcoin USD

    64,022.62
    +1,006.94 (+1.60%)
     
  • CMC Crypto 200

    1,318.78
    -46.34 (-3.40%)
     
  • FTSE 100

    8,311.00
    +97.51 (+1.19%)
     
  • Gold

    2,325.90
    -5.30 (-0.23%)
     
  • Crude Oil

    78.01
    -0.47 (-0.60%)
     
  • 10-Yr Bond

    4.4330
    -0.0560 (-1.25%)
     
  • Nikkei

    38,835.10
    +599.03 (+1.57%)
     
  • Hang Seng

    18,479.37
    -98.93 (-0.53%)
     
  • FTSE Bursa Malaysia

    1,605.68
    +8.29 (+0.52%)
     
  • Jakarta Composite Index

    7,123.61
    -12.28 (-0.17%)
     
  • PSE Index

    6,618.58
    -33.91 (-0.51%)
     

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

After the Food and Drug Administration paused Allogene Therapeutics' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. The FDA's intervention appeared to spur trading by ARK Invest in Beam Therapeutics (NASDAQ: BEAM), Intellia Therapeutics (NASDAQ: NTLA), and Schrödinger (NASDAQ: SDGR).